Amyris, Inc. (NASDAQ:AMRS) shares hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $2.34 and last traded at $2.35, with a volume of 177,202 shares traded. The stock had previously closed at $2.40.

Several research analysts recently issued reports on AMRS shares. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Amyris in a research note on Tuesday, May 23rd. ValuEngine lowered shares of Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, Zacks Investment Research upgraded shares of Amyris from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 16th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $31.13.

The firm’s 50 day moving average price is $3.43 and its 200-day moving average price is $5.68. The stock’s market capitalization is $42.12 million.

Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($1.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by $0.35. The business had revenue of $25.68 million for the quarter, compared to analyst estimates of $23.68 million. The business’s revenue was up 167.5% on a year-over-year basis. During the same period last year, the firm posted ($0.06) earnings per share. Equities research analysts predict that Amyris, Inc. will post ($3.98) earnings per share for the current year.

In other news, Director Patrick Y. Yang purchased 300,000 shares of the firm’s stock in a transaction on Friday, May 19th. The stock was acquired at an average cost of $0.29 per share, with a total value of $87,000.00. Following the completion of the transaction, the director now owns 153,000 shares in the company, valued at approximately $44,370. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 11.30% of the company’s stock.

An institutional investor recently raised its position in Amyris stock. Bank of New York Mellon Corp boosted its stake in shares of Amyris, Inc. (NASDAQ:AMRS) by 16.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 32,768 shares of the biotechnology company’s stock after buying an additional 4,603 shares during the period. Bank of New York Mellon Corp owned approximately 0.17% of Amyris worth $104,000 as of its most recent SEC filing.

COPYRIGHT VIOLATION NOTICE: “Amyris, Inc. (AMRS) Reaches New 52-Week Low at $2.34” was posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.